Webdisclosure.com

Search

ABSCIENCES (EPA:AB) AB Science announces that FDA green-lights U.S. patient enrollment in masitinib Phase 3 study following IND clearance in metastatic castrate-resistant prostate cancer eligible to chemotherapy

Directive transparence : information réglementée

08/01/2020 19:14